An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia

Giuseppe Derosa, 1–3 Angela D’Angelo, 1, 2 Arianna Vanelli, 4 Pamela Maffioli 1, 3 1Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Laboratory of Molecul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Derosa G, D'Angelo A, Vanelli A, Maffioli P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	berberine curcuma inositol banaba chromium picolinate dysglycemia Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/308410f0fb8f4c74adc75ea0fc756f00
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:308410f0fb8f4c74adc75ea0fc756f00
record_format	dspace
spelling	oai:doaj.org-article:308410f0fb8f4c74adc75ea0fc756f002021-12-02T09:40:24ZAn Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia1178-7007https://doaj.org/article/308410f0fb8f4c74adc75ea0fc756f002020-03-01T00:00:00Zhttps://www.dovepress.com/an-evaluation-of-a-nutraceutical-with-berberine-curcumin-inositol-bana-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Giuseppe Derosa, 1–3 Angela D’Angelo, 1, 2 Arianna Vanelli, 4 Pamela Maffioli 1, 3 1Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy; 3Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 4Nutrilinea srl, Gallarate, ItalyCorrespondence: Giuseppe DerosaDepartment of Internal Medicine and Therapeutics, University of Pavia, and Fondazione IRCCS Policlinico San Matteo, P.le C. Golgi, 2, Pavia 27100, ItalyTel +39-0382 526217Fax +39-0382 526259Email giuseppe.derosa@unipv.itAim: To evaluate if a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate (Reglicem®), can ameliorate glycemic status in patients with dysglycemia.Methods: We enrolled 148 patients with impaired fasting plasma glucose or impaired glucose tolerance, not taking any hypoglycemic compounds. Patients were randomized to take nutraceutical or placebo for 3 months, in a randomized, double-blind, placebo-controlled design. Both nutraceutical and placebo were self-administered once a day, 1 tablet during the breakfast.Results: A reduction of fasting and post-prandial plasma glucose was observed with the nutraceutical combination (p < 0.05 vs baseline and p < 0.05 vs placebo, respectively). Furthermore, a decrease of glycated hemoglobin, and fasting plasma insulin was observed with the nutraceutical combination (p < 0.05 vs baseline and p < 0.05 vs placebo, respectively). Then, there was a reduction of homeostasis model assessment index with the nutraceutical combination (p < 0.05 vs baseline and p < 0.05 vs placebo). M value was higher (p < 0.05 vs baseline and p < 0.05 vs placebo) in the nutraceutical combination group at the end of the treatment. We observed a reduction of total cholesterol (TC) (p < 0.05 vs baseline) and triglycerides (Tg) (p < 0.05 vs baseline and p < 0.05 vs placebo) with the nutraceutical combination, respectively. Finally, high sensitivity C-reactive protein was reduced after 3 months with nutraceutical combination therapy (p < 0.05 vs baseline and p < 0.05 vs placebo, respectively).Conclusion: A nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate can be helpful in improving glyco-metabolic compensation, TC and Tg value, and in reducing inflammatory status in patients with dysglycemia.Keywords: Berberine, Curcuma, Inositol, Banaba, Chromium Picolinate, dysglycemiaDerosa GD'Angelo AVanelli AMaffioli PDove Medical Pressarticleberberinecurcumainositolbanabachromium picolinatedysglycemiaSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 653-661 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	berberine curcuma inositol banaba chromium picolinate dysglycemia Specialties of internal medicine RC581-951
spellingShingle	berberine curcuma inositol banaba chromium picolinate dysglycemia Specialties of internal medicine RC581-951 Derosa G D'Angelo A Vanelli A Maffioli P An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia
description	Giuseppe Derosa, 1–3 Angela D’Angelo, 1, 2 Arianna Vanelli, 4 Pamela Maffioli 1, 3 1Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy; 3Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 4Nutrilinea srl, Gallarate, ItalyCorrespondence: Giuseppe DerosaDepartment of Internal Medicine and Therapeutics, University of Pavia, and Fondazione IRCCS Policlinico San Matteo, P.le C. Golgi, 2, Pavia 27100, ItalyTel +39-0382 526217Fax +39-0382 526259Email giuseppe.derosa@unipv.itAim: To evaluate if a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate (Reglicem®), can ameliorate glycemic status in patients with dysglycemia.Methods: We enrolled 148 patients with impaired fasting plasma glucose or impaired glucose tolerance, not taking any hypoglycemic compounds. Patients were randomized to take nutraceutical or placebo for 3 months, in a randomized, double-blind, placebo-controlled design. Both nutraceutical and placebo were self-administered once a day, 1 tablet during the breakfast.Results: A reduction of fasting and post-prandial plasma glucose was observed with the nutraceutical combination (p < 0.05 vs baseline and p < 0.05 vs placebo, respectively). Furthermore, a decrease of glycated hemoglobin, and fasting plasma insulin was observed with the nutraceutical combination (p < 0.05 vs baseline and p < 0.05 vs placebo, respectively). Then, there was a reduction of homeostasis model assessment index with the nutraceutical combination (p < 0.05 vs baseline and p < 0.05 vs placebo). M value was higher (p < 0.05 vs baseline and p < 0.05 vs placebo) in the nutraceutical combination group at the end of the treatment. We observed a reduction of total cholesterol (TC) (p < 0.05 vs baseline) and triglycerides (Tg) (p < 0.05 vs baseline and p < 0.05 vs placebo) with the nutraceutical combination, respectively. Finally, high sensitivity C-reactive protein was reduced after 3 months with nutraceutical combination therapy (p < 0.05 vs baseline and p < 0.05 vs placebo, respectively).Conclusion: A nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate can be helpful in improving glyco-metabolic compensation, TC and Tg value, and in reducing inflammatory status in patients with dysglycemia.Keywords: Berberine, Curcuma, Inositol, Banaba, Chromium Picolinate, dysglycemia
format	article
author	Derosa G D'Angelo A Vanelli A Maffioli P
author_facet	Derosa G D'Angelo A Vanelli A Maffioli P
author_sort	Derosa G
title	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia
title_short	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia
title_full	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia
title_fullStr	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia
title_full_unstemmed	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia
title_sort	evaluation of a nutraceutical with berberine, curcumin, inositol, banaba and chromium picolinate in patients with fasting dysglycemia
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/308410f0fb8f4c74adc75ea0fc756f00
work_keys_str_mv	AT derosag anevaluationofanutraceuticalwithberberinecurcumininositolbanabaandchromiumpicolinateinpatientswithfastingdysglycemia AT dangeloa anevaluationofanutraceuticalwithberberinecurcumininositolbanabaandchromiumpicolinateinpatientswithfastingdysglycemia AT vanellia anevaluationofanutraceuticalwithberberinecurcumininositolbanabaandchromiumpicolinateinpatientswithfastingdysglycemia AT maffiolip anevaluationofanutraceuticalwithberberinecurcumininositolbanabaandchromiumpicolinateinpatientswithfastingdysglycemia AT derosag evaluationofanutraceuticalwithberberinecurcumininositolbanabaandchromiumpicolinateinpatientswithfastingdysglycemia AT dangeloa evaluationofanutraceuticalwithberberinecurcumininositolbanabaandchromiumpicolinateinpatientswithfastingdysglycemia AT vanellia evaluationofanutraceuticalwithberberinecurcumininositolbanabaandchromiumpicolinateinpatientswithfastingdysglycemia AT maffiolip evaluationofanutraceuticalwithberberinecurcumininositolbanabaandchromiumpicolinateinpatientswithfastingdysglycemia
_version_	1718398057299574784

An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia

Ejemplares similares